Nucynta (Tapentadol HCl) Patent Expiration, LOE Window & CMS Spending
Nucynta (Tapentadol HCl) by Collegium: FDA Orange Book LOE 2027-01-03, 2 AB generics, $68.0M 2024 CMS Part D & Medicaid spend, and 32 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Collegium |
| FDA Application & Pathway | N022304 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2027-01-03 |
| Orange Book Patents (*PED Extensions) | 0 patents (1 *PED) |
| Active AB-Rated Generic Competitors | 2 |
| 2024 CMS Total Public Spend | $68.0M |
| 2024 Medicare Part D Spend | $56.1M |
| 2024 Medicaid Spend | $11.9M |
| Reported Wholesale Price Change (CA SB 17) | 32 WAC filings (max 38.9% 2-yr change) |